

EUROPEAN
CURRICULUM VITAE



PERSONAL INFORMATIONS

Name ALESSANDRA TEDESCHI
Address PIAZZA OSPEDALE MAGGIORE ,3 MILANO
Telephone 00390264442668
Fax 00390264442033
E-mail alessandra.tedeschi@ospedaleniguarda.it
Social Security Number TDSLSN64T46H501H
Nazionalità Italian
Date and place of bearth 06/12/1964, ROMA ITALY

WORK EXPERIENCE	
Date Position	<i>From April 1999-today</i> Senior consultant in Haematology at the Department of Oncology/Haematology Division of Haematology ASST Grande Ospedale Metropolitano Niguarda
Responsabilities	<i>From 2003-today</i> -Clinical care of patients affected by Chronic Lymphocytic Leukemia and indolent non follicular Lymphoproliferative disorders, Rich -Chair of the research clinical program in Chronic Lymphocytic Leukemia, Marginal Zone lymphoma, Waldenström Macroglobulinemia, Hairy Cell Leukemia <i>From 1999 to 2003</i> Clinical care in the bone marrow transplantation unit in both autologous and allogeneic bone marrow transplant
Date Position	<i>July 1997-March 1999</i> Research stage on a project regarding the purging of peripheral blood stem cell transplant in lymphoproliferative disorders at the Department of Haematology ASST Grande Ospedale Metropolitano Niguarda
Date Position	<i>October 1996- July 1997</i> Research grant on a project regarding cord blood transplants in Hematological malignancies Department of Haematology of ASST Grande Ospedale Metropolitano Niguarda
Research	Principal Investigator of phase II and III sponsored randomized international trials Principal Investigator of Institutional of phase II trials Principal Investigator of phase I trials
Education and	

Training	
Date	1998 Research stage at the MD Anderson Cancer Center, Houston, Texas on Chronic Lymphocytic leukemia
Date Title and qualification awarded	1992-1996 Fellowship in Haematology at the Ancona University Medical School. University of Ancona Italy
Date Title and qualification awarded	1996 PhD on Clinical Haematology University of Ancona Italy
Date Title and qualification awarded	Accademic year 1989/90 Medical Doctor Degree Bologna University Medical School
Memberships	Italian of Society of Hematology (SIE) European Hematology Association (EHA) European Research Initiative on CLL (ERIC)
Main Invited Presentations	Congress of the European Hematology Association (2019), Education Session on Waldenstrom Macroglobulinemia Congress of the Italian Society of Hematology , Education Session on Chronic Lymphocytic Leukemia Congress of the Italian Society of Hematology (2019) , Education Session on Waldenstrom Macroglobulinemia Society of Hematology, what is fitness in the era of target agents
Bibliometrics	Publications 133 Hindex 35
Foreign Languages	English Greek

Milano 06 July 2022

Autorizzo il trattamento dei miei dati personali ai sensi del D.lgs. 196 del 30 giugno 2003"

Dottorressa Alessandra Tedeschi



PUBLICATIONS

136. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNOVATE Study Buske C, **Tedeschi A**, Trotman J, García-Sanz R, MacDonald D, Leblond V, Mahe B, Herbaux C, Matous JV, Tam CS, Heffner LT, Varettoni M, Palomba ML, Shustik C, Kastritis E, Treon SP, Ping J, Hauns B, Arango-Hisijara I, Dimopoulos MA. J clin Oncol 2022 Jan 1;40(1):52-62.
135. Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial Trotman J, Buske C, **Tedeschi A**, Matous JV, MacDonald D, Tam CS, Tournilhac O, Ma S, Treon SP, Oriol A, Ping J, Briso EM, Arango-Hisijara I, Dimopoulos MA. Blood 2021 Nov 1;127(21):5793-5800
134. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies Tam CS, Dimopoulos MA, Garcia-Sanz R, Trotman J, Opat S, Roberts AW, Owen RG, Song Y, Xu W, Zhu J, Li J, Qiu L, D'Sa S, Jurczak W, Cull G, Marlton P, Gottlieb DJ, Munoz J, Phillips T, Du C, Ji M, Zhou L, Guo H, Zhu H, Chan WY, Cohen A, Novotny W, Huang J, **Tedeschi A**. Blood Adv 2021 Nov 1;bloodadvances.2021005621.
133. Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib Mauro FR, Giannarelli D, Visentin A, Reda G, Sportoletti P, Frustaci AM, Chiarenza A, Ciolli S, Vitale C, Laurenti L, De Paoli L, Murru R, Gentile M, Rigolin GM, Levato L, Giordano A, Del Poeta G, Stelitano C, Ielo C, Noto A, Guarente V, Molica S, Coscia M, **Tedeschi A**, Gaidano G, Cuneo A, Foà R, Martelli M, Girmenia C, Gentile G, Trentin L. Cancers 2021 Jun 29;13(13):3240
132. Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib? **Tedeschi A**, Frustaci AM, Mauro FR, Chiarenza A, Coscia M, Ciolli S, Reda G, Laurenti L, Varettoni M, Murru R, Barate C, Sportoletti P, Greco A, Borella C, Rossi V, Deodato M, Biagi A, Zamprogn G, Pelle AC, Lapietra G, Vitale C, Morelli F, Cassin R, Fresa A, Cavalloni C, Postorino M, Ielo C, Cairoli R, Di Raimondo F, Montillo M, Del Poeta G. Blood Advances 2021 Dec 28;5(24):5490-5500.
131. Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells Trojani A, Di Camillo B, Bossi LE, Leuzzi L, Greco A, **Tedeschi A**, Frustaci AM, Deodato M, Zamprogn G, Beghini A, Cairoli R. Cancers 2021 Apr 12;13(8):1837.
130. A multicenter total therapy strategy for *de novo* adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol Chiaretti S, Ansuinelli M, Vitale A, Elia L, Matarazzo M, Piciocchi A, Fazi P, Di Raimondo F, Santoro L, Fabbiano F, Califano C, Martinelli G, Ronco F, Ferrara F, Cascavilla N, Bigazzi C, **Tedeschi A**, Sica S, Di Renzo N, Melpignano A, Beltrami G, Vignetti M, Foa R. Haematological 2021 Jul 1;106(7):1828-1838
129. The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma Opat S, **Tedeschi A**, Linton K, McKay P, Hu B, Chan H, Jin J, Sobieraj-Teague M, Zinzani PL, Coleman M, Thieblemont C, Browett P, Ke X, Sun M, Marcus R, Portell CA, Ardeshtna K, Bijou F, Walker P, Hawkes EA, Mapp S, Ho SJ, Talaulikar D, Zhou KS, Co M, Li X, Zhou W, Cappellini M, Tankersley C, Huang J, Trotman J. Clinica Cancer Reserach 2021 Dec 1;27(23):6323-6332.
128. Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs Vitale C, Salvetti C, Griggio V, Porrazzo M, Schiattone L, Zamprogn G, Visentin A, Vassallo F, Cassin R, Rigolin GM, Murru R, Laurenti L, Rivela P, Marchetti M, Pennese E, Gentile M, Boccellato E, Perutelli F, Montalbano MC, De Paoli L, Reda G, Orsucci L, Trentin L, Cuneo A, **Tedeschi A**, Scarfò L, Gaidano G, Mauro FR, Foà R, Boccadoro M, Coscia M. Blood 2021 Jun 24;137(25):3507-3517
127. What Is Fitness in the Era of Targeted Agents? Frustaci AM, Deodato M, Zamprogn G, Cairoli R, Montillo M, **Tedeschi A**. Clyn Lymphoma Myeloma Leukemia 2021 Dec 3;S2152-2650(21)02444-7.
126. Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia Martinelli G, Papayannidis C, Piciocchi A, Robustelli V, Soverini S, Terragna C, Marconi G, Lemoli RM, Guolo F, Fornaro A, Lunghi M, de Fabritiis P, Candoni A, Selleri C, Simonetti F, Bocchia M, Vitale A, Frison L, **Tedeschi A**, Cuneo A, Bonifacio M, Martelli MP, D'Ardia S, Trappolini S, Tosi P, Galieni P, Fabbiano F, Abbenante MC, Granier M, Zhu Z, Wang M, Sartor C, Paolini S, Cavo M, Foà R, Fazi P, Vignetti M, Baccarani M. Blood Avances 2021 Oct 14;bloodadvances.2021004821. doi: 10.1182/bloodadvances.2021004821
125. Reply to "CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report" Analysis of six hematological centers in Lombardy : Reda G, Noto A, Cassin R, Zamprogn G, Borella C, Scarfò L, Farina L, Molteni A, Ghia P, **Tedeschi**

A, Montillo M; On behalf of CLL commission of Lombardy Hematology Network (REL) *Leukemia* 2020 Sep;34(9):2531-2532.

124. Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group Herishanu Y, Shaulov A, Fineman R, Bašić-Kinda S, Aviv A, Wasik-Szczepanek E, Jaksic O, Zdrenghea M, Greenbaum U, Mandac I, Simkovic M, Morawska M, Benjamini O, Spacek M, Nemets A, Bairey O, Trentin L, Ruchlemer R, Laurenti L, Stanca Ciocan O, Doubek M, Shvidel L, Dali N, Mirás F, De Meûter A, Dimou M, Mauro FR, Coscia M, Bumbea H, Szász R, Tadmor T, Gutwein O, Gentile M, Scarfò L, **Tedeschi A**, Sportoletti P, Gimeno Vázquez E, Marquet J, Assouline S, Papaioannou M, Braester A, Levato L, Gregor M, Rigolin GM, Loscertales J, Medina Perez A, Nijziel MR, Popov VM, Collado R, Slavutsky I, Itchaki G, Ringelstein S, Goldschmidt N, Perry C, Levi S, Polliack A, Ghia Am J Hematol 2020 Jun;95(6):604-611

123. The management of chronic lymphoproliferative disorders at the time of SARS-Covid2 pandemic: weathering the storm Frustaci AM, Zamproga G, Deodato M, Cairoli R, Montillo M, **Tedeschi A**. *Leuk Lymphoma* 2020 61(13): 3278-3279

122. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study Cuneo A, Mato AR, Rigolin GM, Piciocchi A, Gentile M, Laurenti L, Allan JN, Pagel JM, Brander DM, Hill BT, Winter A, Lamanna N, Tam CS, Jacobs R, Lansigan F, Barr PM, Shadman M, Skarbnik AP, Pu JJ, Sehgal AR, Schuster SJ, Shah NN, Ujjani CS, Roeker L, Orlandi EM, Billio A, Trentin L, Spacek M, Marchetti M, **Tedeschi A**, Ilariucci F, Gaidano G, Doubek M, Farina L, Molica S, Di Raimondo F, Coscia M, Mauro FR, de la Serna J, Medina Perez A, Ferrarini I, Cimino G, Cavallari M, Cucci R, Vignetti M, Foà R, Ghia P; GIMEMA, European Research Initiative (ERIC) on CLL, US study group. *Cancer Med* 2020; 9(22):8468-8479

121. What is fitness in the era of target agents **Tedeschi A**. *Clin Lymphoma Myeloma Leuk* 2020 Sep; 20 Suppl1:S84-S86

120. Duvelisib for the treatment of chronic lymphocytic leukemia Frustaci AM, **Tedeschi A**, Deodato M, Zamproga G, Cairoli R, Montillo M. *Expert Opin Pharmacother* 2020 Aug; 21(11):1299-1309 *Expert Opin Pharmacother*. 2020 Aug;21(11):1299-1309.

119. Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion Tam CS, Robak T, Ghia P, Kahl BS, Walker P, Janowski W, Simpson D, Shadman M, Ganly PS, Laurenti L, Opat S, Tani M, Ciepluch H, Verner E, Šimkovič M, Österborg A, Trněný M, **Tedeschi A**, Paik JC, Kuwahara SB, Feng S, Ramakrishnan V, Cohen A, Huang J, Hillmen P, Brown JR. *Haematologica* 2020 Oct 13; 106(9): 2354-2363

118. *A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study* Constantine S. Tam, Stephen Opat, Shirley D'Sa, Wojciech Jurczak, Hui-Peng Lee, Gavin Cull, Roger G. Owen, Paula Marlton, Björn E. Wahlin, Ramón García Sanz, Helen McCarthy, Stephen Mulligan, **Alessandra Tedeschi**, Jorge J. Castillo, Jaroslaw Czyz, Carlos Fernández de Larrea, David Belada, Edward Libby, Jeffrey V. Matous, Marina Motta, Tanya Siddiqi, Monica Tani, Marek Trneny, Monique C. Minnema, Christian Buske, Veronique Leblond, Judith Trotman, Wai Y. Chan, Jingjing Schneider, Sunhee Ro, Aileen Cohen, Jane Huang, Meletios Dimopoulos *Blood*. 2020 Oct 29; 136(18): 2038–2050. Prepublished online 2020 Jul 31. doi: 10.1182/blood.2020006844

117. *Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up* Judith Trotman, Stephen Opat, David Gottlieb, David Simpson, Paula Marlton, Gavin Cull, Javier Munoz, **Alessandra Tedeschi**, Andrew W. Roberts, John F. Seymour, Siminder Kaur Atwal, Yiling Yu, William Novotny, Eric Holmgren, Ziwen Tan, James D. Hilger, Jane Huang, Constantine S. Tam *Blood*. 2020 Oct 29; 136(18): 2027–2037

116. *Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic* Dipti Talaulikar, Ranjana H. Advani, Andrew R. Branagan, Christian Buske, Meletios A. Dimopoulos, Shirley D'Sa, Maria J. Kersten, Veronique Leblond, Monique C. Minnema, Roger G. Owen, Maria Lia Palomba, **Alessandra Tedeschi**, Judith Trotman, Marzia Varettoni, Josephine M. Vos, Steven P. Treon, Efstathios Kastritis, Jorge J. Castillo *Hemasphere*. 2020 Aug; 4(4): e433. Published online 2020 Jul 30. doi: 10.1097/HS9.0000000000000433

115. *Health-related quality of life in Waldenström Macroglobulinemia and IgM-related disorders: A single institution experience*. Frustaci AM, Nichelatti M, Deodato M, Zamproga G, Minga P, Pioltelli ML, Cairoli R, **Tedeschi A**. *Hematol Oncol*. 2019 Dec 18. doi: 10.1002/hon.2699

114. *Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study.*114 Tam CS, Siddiqi T, Allan JN, Kipps TJ, Flinn IW, Kuss BJ, Opat S, Barr PM, **Tedeschi A**, Jacobs R, Badoux XC, Ghia P, Sukbuntherng J, Salem AH, Russell K, Eckert K, Zhou C, Ninomoto J, James DF, Wierda WG. *Blood*. 2019 Nov 13;134(Supplement_1):35. doi: 10.1182/blood-2019-121424.
113. *Chemo-immunotherapy for Older Patients with Chronic Lymphocytic Leukemia - Time to Retire?* Scarfò L, **Tedeschi A**. *Hemasphere*. 2019 Aug 7;3(4):e278. doi: 10.1097/HS9.0000000000000278. eCollection 2019 Aug.
112. *Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.* Jan A. Burger, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, **Alessandra Tedeschi**, Osnat Bairey, Peter Hillmen, Steven E. Coutre, Stephen Devereux, Sebastian Grosicki, Helen McCarthy, David Simpson, Fritz Offner, Carol Moreno, Sandra Dai, Indu Lal, James P. Dean, Thomas J. Kipps. *Leukemia*. 2020; 34(3): 787–79
111. *A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.* **Alessandra Tedeschi**, Richard Greil, Fatih Demirkan, Tadeusz Robak, Carol Moreno, Paul M. Barr, Bertrand Anz, David Simpson, Gianluca Gaidano, Osnat Bairey, Don Stevens, Devinder Gill, Ian W. Flinn, Thomas J. Kipps, Jan A. Burger, Jennifer Lin, Thomas Webb, Viktor Fedorov, Lori Styles, John G. Gribben. *Haematologica*. 2020 Apr; 105(4): e164–e168
110. *Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.* Varettoni M, Boveri E, Zibellini S, **Tedeschi A**, Candido C, Ferretti VV, Rizzo E, Doni E, Merli M, Farina L, Goldaniga M, Galli A, Rattotti S, Frustaci AM, Deodato M, Bandiera L, Isimbaldi G, Uccella S, Cabras AD, Gianelli U, Baldini L, Paulli M, Arcaini L. *Am J Hematol*. 2019 Nov;94(11):1193-1199. doi: 10.1002/ajh.25600. Epub 2019 Sep 9.
109. *Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia.* F, Moia R, Favini C, Spaccarotella E, De Paoli L, Bruscaggin A, Spina V, Terzi-di-Bergamo L, Arruga F, Tarantelli C, Deambrogi C, Rasi S, Adhinaveni R, Patriarca A, Favini S, Sagiraju S, Jabangwe C, Kodipad AA, Peroni D, Mauro FR, Del Giudice I, Forconi F, Cortelezzi A, Zaja F, Bomben R, Rossi FM, Visco C, Chiarenza A, Rigolin GM, Marasca R, Coscia M, Perbellini O, **Tedeschi A**, Laurenti L, Motta M, Donaldson D, Weir P, Mills K, Thornton P, Lawless S, Bertoni F, Del Poeta G, Cuneo A, Follenzi A, Gattei V, Boldorini RL, Catherwood M, Deaglio S, Foà R, Gaidano G, Rossi D. *Haematologica*. 2019 Aug 1. pii: haematol.2019.219550. doi: 10.3324/haematol.2019.219550.
108. *Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience.* Innocenti I, Morelli F, Autore F, Piciocchi A, Frustaci A, Mauro FR, Schiattone L, Trentin L, Del Poeta G, Reda G, Rigolin GM, Ibatì A, Ciolli S, Coscia M, Sportoletti P, Murru R, Levato L, Gentile M, D'Arena G, Efremov DG, **Tedeschi A**, Scarfò L, Cuneo A, Foà R, Laurenti L. *Br J Haematol*. 2019 Oct;187(1):e8-e11.
107. *Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.* Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, Harrup R, Johnston PB, Marlton P, Munoz J, Seymour JF, Simpson D, **Tedeschi A**, Elstrom R, Yu Y, Tang Z, Han L, Huang J, Novotny W, Wang L, Roberts AW. *Blood*. 2019 Sep 12;134(11):851-859.
106. *A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia.* Visentin A, Deodato M, Mauro FR, Autore F, Reda G, Vitale C, Molica S, Rigolin GM, Piazza F, Cesini L, **Tedeschi A**, Laurenti L, Cassin R, Coscia M, Cuneo A, Foà R, Semenzato G, Trentin L. *Hematol Oncol*. 2019 Oct;37(4):508-512.
105. *Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study.* Luminari S, Merli M, Rattotti S, Tarantino V, Marcheselli L, Cavallo F, Varettoni M, Bianchi B, Merli F, **Tedeschi A**, Cabras G, Re F, Visco C, Torresan Delamain M, Cencini E, Spina M, Ferrero S, Ferrari A, Deodato M, Mannina D, Annibali O, Rago A, Orsucci L, Defrancesco I, Frigeni M, Cesaretti M, Arcaini L. *Blood*. 2019 Sep 5;134(10):798-801
104. *Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia.* Frustaci AM, **Tedeschi A**, Deodato M, Zamprogna G, Cairoli R, Montillo M. *Future Oncol*. 2019 Jul;15(19):2227-2239
103. *Ibrutinib for the treatment of chronic lymphocytic leukemia* Deodato M, Frustaci AM, Zamprogna G, Cairoli R, Montillo M, **Tedeschi A**. *Expert Rev Hematol*. 2019 May;12(5):273-284.

102. *Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.* O'Brien SM, Byrd JC, Hillmen P, Coutre S, Brown JR, Barr PM, Barrientos JC, Devereux S, Robak T, Reddy NM, Kipps TJ, **Tedeschi A**, Cymbalista F, Ghia P, Chang S, Ninomoto J, James DF, Burger JA. *Am J Hematol.* 2019 May;94(5):554-562.
101. *Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies* Burger JA, Cramer P, Barr PM, Dilhuydy MS, Mato A, Byrd JC, Chang S, Graef T, Lin T, **Tedeschi A**. *Br J Haematol.* 2019 Jul;186(1):175-180
100. *Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network.* Rattotti S, Ferretti VV, Rusconi C, Rossi A, Fogazzi S, Baldini L, Pioltelli P, Balzarotti M, Farina L, Ferreri AJM, Laszlo D, Speziale V, Varettoni M, Sciarra R, Morello L, **Tedeschi A**, Frigeni M, Defrancesco I, Zerbi C, Flospergher E, Nizzoli ME, Morra E, Arcaini L; "Rete Ematologica Lombarda" (REL - Hematology Clinical Network of Lombardy - Lymphoma Workgroup). *Hematol Oncol.* 2019 Apr;37(2):160-167
99. *Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment.* Gounari M, Ntoufa S, Gerousi M, Vilia MG, Moysiadis T, Kotta K, Papakonstantinou N, Scarfò L, Agathangelidis A, Fonte E, Ranghetti P, Nenou A, Xochelli A, Coscia M, **Tedeschi A**, Stavroyianni N, Muzio M, Stamatopoulos K, Ghia P. *Leukemia.* 2019 Apr;33(4):1030-1051
98. *Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study.* Castillo JJ, Itchaki G, Paludo J, Varettoni M, Buske C, Eyre TA, Chavez JC, Shain KH, Issa S, Palomba ML, Pasvolsky O, Simpson D, Talaulikar D, Tam CS, **Tedeschi A**, Ansell SM, Nayak L, Treon SP. *Blood.* 2019 Jan 24;133(4):299-305
97. *Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial* Moreno C, Greil R, Demirkan F, **Tedeschi A**, Anz B, Larratt L, Simkovic M, Samoilova O, Novak J, Ben-Yehuda D, Strugov V, Gill D, Gribben JG, Hsu E, Lih CJ, Zhou C, Clow F, James DF, Styles L, Flinn IW. *Lancet Oncol.* 2019 Jan;20(1):43-56.
96. *Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up* Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, **Tedeschi A**, Buske C; ESMO Guidelines Committee. *Ann Oncol.* 2019 May 1;30(5):860-862
95. *Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia* **Tedeschi A**, Conticello C, Rizzi R, Benevolo G, Laurenti L, Petrucci MT, Zaja F, Varettoni M. *Hematol Oncol.* 2018 Sep 7
94. *Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: a cross-trial comparison of phase 3 studies.* Robak T, Burger JA, **Tedeschi A**, Barr PM, Owen C, Bairey O, Hillmen P, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre SE, Quach H, Gaidano G, Maslyak Z, Stevens DA, Moreno C, Gill DS, Flinn IW, Gribben JG, Mokattrin A, Cheng M, Styles L, James DF, Kipps TJ, Ghia P. *Am J Hematol.* 2018 Aug 20
93. *Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.* O'Brien S, Hillmen P, Coutre S, Barr PM, Fraser G, **Tedeschi A**, Burger JA, Dilhuydy MS, Hess G, Moreno C, Cramer P, Liu E, Chang S, Vermeulen J, Styles L, Howes A, James DF, Patel K, Graef T, Valentino R. *Clin Lymphoma Myeloma Leuk.* 2018 Oct;18(10):648-657
92. *Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.* Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, **Tedeschi A**, Buske C; ESMO Guidelines Committee. *Annals Oncology* 2018 July 5
91. *Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review.* Buske C, Sadullah S, Kastritis E, **Tedeschi A**, García-Sanz R, Bolkun L, Leleu X, Willenbacher W, Hájek R, Minnema MC, Cheng M, Bilotti E, Graef T, Dimopoulos MA; European Consortium for Waldenström's Macroglobulinemia. *Lancet Haematol.* 2018 Jul;5(7):e299-e309
90. *Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.* Barr PM, Robak T, Owen C, **Tedeschi A**, Bairey O, Bartlett NL, Burger JA, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James D, Kipps TJ, Ghia P. *Haematologica.* 2018 Sep;103(9):1502-1510

89. *A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.* Tam CS, LeBlond V, Novotny W, Owen RG, **Tedeschi A**, Atwal S, Cohen A, Huang J, Buske C. *Future Oncol.* 2018 Sep;14(22):2229-2237

88. *Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.* Cuneo A, Follows G, Rigolin GM, Piciocchi A, **Tedeschi A**, Trentin L, Perez AM, Coscia M, Laurenti L, Musuraca G, Farina L, Delgado AR, Orlandi EM, Galieni P, Mauro FR, Visco C, Amendola A, Billio A, Marasca R, Chiarenza A, Meneghini V, Ilariucci F, Marchetti M, Molica S, Re F, Gaidano G, Gonzalez M, Forconi F, Ciolli S, Cortelezzi A, Montillo M, Smolej L, Schuh A, Eyre TA, Kennedy B, Bowles KM, Vignetti M, de la Serna J, Moreno C, Foà R, Ghia P; GIMEMA, European Research Initiative on CLL (ERIC) and UK CLL forum. *Haematologica.* 2018 Jul;103(7):1209-1217

87. *Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.* Boriani G, Corradini P, Cuneo A, Falanga A, Foà R, Gaidano G, Ghia PP, Martelli M, Marasca R, Massaia M, Mauro FR, Minotti G, Molica S, Montillo M, Pinto A, **Tedeschi A**, Vitolo U, Zinzani PL. *Hematol Oncol.* 2018 Mar 7.

86. *Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients.* Molica S, Levato L, Mirabelli R, Tedeschi A, Lentini M. *Leuk Lymphoma.* 2018 Feb 21:1-3.

85. *Waldenstrom's Macroglobulinemia: An Update.* Mazzucchelli M, Frustaci AM, Deodato M, Cairoli R, **Tedeschi A**. *Mediterr J Hematol Infect Dis.* 2018 Jan 1;10(1):e2018004

84. *Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.* Frustaci AM, **Tedeschi A**, Deodato M, Mazzucchelli M, Cairoli R, Montillo M. *Future Oncol.* 2018 Apr;14(8):681-697.

83. *Survival adjusting for crossover: phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.* Coutre S, **Tedeschi A**, Robak T, Barr PM, Owen C, Bairey O, Burger J, Zhou C, Styles L, James DF, Kipps TJ. *Haematologica.* 2018 Jun;103(6):e249-e251

82. *Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials* Brown JR, Moslehi J, O'Brien S, Ghia P, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps TJ, Coutre S, Dilhuydy MS, Cramer P, **Tedeschi A**, Jaeger U, Dreyling M, Byrd JC, Howes A, Todd M, Vermeulen J, James DF, Clow F, Styles L, Valentino R, Wildgust M, Mahler M, Burger JA. *Haematologica.* 2017 Oct;102(10):1796-1805

81. *Is HBV prophylaxis required during CLL treatment with ibrutinib?* **Tedeschi A**, Frustaci AM, Mazzucchelli M, Cairoli R, Montillo M. *Leuk Lymphoma.* 2017 Dec;58(12):2966-296

80. *Factors predicting survival in chronic lymphocytic leukemia patients developing Richter Syndrome transformation into Hodgkin Lymphoma* Mauro FR, Galieni P, **Tedeschi A**, Laurenti L, Del Poeta G, Reda G, Motta M, Gozzetti A, Murru R, Caputo MD, Campanelli M, Frustaci AM, Innocenti I, Raponi S, Guarini A, Morabito F, Foà R, Gentile M. *Am J Hematol.* 2017 Jun;92(6):529-535

79. *Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the Resonate Study* Montillo M, O'Brien S, Tedeschi A, Byrd JC, Dearden C, Gill D, Brown JR, Barrientos JC, Mulligan SP, Furman RR, Cymbalista F, Plascencia C, Chang S, Hsu E, James DF, Hillmen P. *Blood Cancer J.* 2017 Feb 3;7(2)

78. *Front-line treatment of CLL in the era of novel agents* Robak T, Stilgenbauer S, **Tedeschi A**. *Cancer Treat Rev.* 2017 Feb;53:70-78

77. *Ibrutinib for patients with rituximab refractory Waldenstrom's Macroglobulinemia (iNOVATE): an open-label substudy of an international multicentre phase 3 trial* Dimopoulos MA, Trotman J, **Tedeschi A**, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, García-Sanz R, Cornell RF, de Larrea CF, Castillo JJ, Granell M, Kyrtonis MC, Leblond V, Symeonidis A, Kastritis E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C; iNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia. *Lancet Oncol.* 2017 Feb;18(2):241-25

76. *BDR in newly diagnosed patients with WM final analysis of a phase 2 study after a minimum follow-up of 6 years* Gavriatopoulou M, García-Sanz R, Kastritis E, Morel P, Kyrtonis MC, Michalis E, Kartasis Z, Leleu X, Palladini G, **Tedeschi A**, Gika D, Merlini G, Sonneveld P, Dimopoulos MA. *Blood.* 2017 Jan 26;129(4):456-459

75. *A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia final results of the GIMEMA LAL 0904 study* Chiaretti S, Vitale A, Vignetti M, Piciocchi A, Fazi P, Elia L, Falini B, Ronco F, Ferrara F, De Fabritiis P, Luppi M, La Nasa G, **Tedeschi A**, Califano C, Fanin R, Dore F, Mandelli F, Meloni G, Foà R. *Haematologica*. 2016 Dec;101(12):1544-1552.
74. *Ofatumumab plus chlorambucil as a first-line therapy in less fit patients* Frustaci AM, Tedeschi A, Picardi P, Mazzucchelli M, Cairoli R, Montillo M. *Ther Adv Hematol*. 2016 Aug;7(4):222-30. doi: 10.1177/2040620716648567. Epub 2016 May 21. Review.
73. *Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?* Frustaci AM, Montillo M, Picardi P, Mazzucchelli M, Cairoli R, **Tedeschi A**. *Expert Rev Hematol*. 2016 Jul;9(7):679-93
72. *Bing Neel Syndrome in a Previously Untreated Patient With Waldenström's Macroglobulinemia: Contribution of MYD88 L265P Mutation on Cerebrospinal Fluid*. Frustaci AM, Rusconi C, Picardi P, Veronese S, Montillo M, Cairoli R, **Tedeschi A**. *Clin Lymphoma Myeloma Leuk*. 2016 Jan;16(1)
71. *Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study*. Castillo JJ, D'Sa S, Lunn MP, Minnema MC, **Tedeschi A**, Lansigan F, Palomba ML, Varettoni M, Garcia-Sanz R, Nayak L, Lee EQ, Rinne ML, Norden AD, Ghobrial IM, Treon SP. *Br J Haematol*. 2016 Mar;172(5):709-15. doi: 10.1111/bjh.13883. Epub 2015 Dec 21.
70. *Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia*. Xu L, Hunter ZR, Tsakmaklis N, Cao Y, Yang G, Chen J, Liu X, Kanan S, Castillo JJ, Tai YT, Zehnder JL, Brown JR, Carrasco RD, Advani R, Sabile JM, Argyropoulos K, Lia Palomba M, Morra E, Trojani A, Greco A, **Tedeschi A**, Varettoni M, Arcaini L, Munshi NM, Anderson KC, Treon SP. *Br J Haematol*. 2016 Mar;172(5):735-44
69. *Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia*. Burger JA, **Tedeschi A**, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ; RESONATE-2 Investigators. *N Engl J Med*. 2015 Dec 17;373(25):2425-37
68. *Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia*. Frustaci AM, **Tedeschi A**, Picardi P, Cairoli R, Montillo M. *Biologics: targets & therapy*. 2015;9:75-86
67. *A Phase II study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent non-follicular non-Hodgkin's Lymphoma*. Luminari S, Goldaniga M, Cesaretti M, Orsucci L, Tucci A, Pulsoni A, Salvi F, Arcaini L, Carella AM, Tedeschi A, Pinto A, Stelitano C, Baldini. *Leukemia & lymphoma*. 2015;17:1-31
66. *Toll-Like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling activation and proliferation* Fonte E, Agathangelidis A, Reverberi D, Ntoufa S, Scarfò L, Ranghetti P, Cutrona G, **Tedeschi A**, Xochelli A, Caligaris-Cappio F, Ponzoni M, Belessi C, Davis Z, Piris MA, Oscier D, Ghia P, Stamatopoulos K, Muzio M. *Haematologica*. 2015;100:1460-1468
65. *A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients* **Tedeschi A**, Rossi D, Motta M, Quaresmini G, Rossi M, Coscia M, Anastasia A, Rossini F, Cortelezzi A, Nador G, Scarfò L, Cairoli R, Frustaci AM, Dalceggio D, Picardi P, De Paoli L, Orlandi E, Rambaldi A, Massaia M, Gaidano G, Montillo M. *Haematologica*. 2015;100:501-504
64. *Molecular prediction of durable response after first line fludarabine cyclophosphamide rituximab in CLL* Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A, Bulian P, Visco C, Mauro FR, Morabito F, Cortelezzi A, Zaja F, Forconi F, Laurenti L, Del Giudice I, Gentile M, Vincelli I, Motta M, Coscia M, Rigolin GM, **Tedeschi A**, Neri A, Marasca R, Perbellini O, Moreno C, Del Poeta G, Massaia M, Zinzani PL, Montillo M, Cuneo A, Gattei V, Foà R, Gaidano G. *Blood*. 2015; 126(16):1921-4
63. *Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia* **Tedeschi A**, Picardi P, Ferrero S, Benevolo G, Margiotta Casaluci G, Varettoni M, Baratè C, Motta M, Gini G, Goldaniga MC, Visco C, Zaja F, Belsito Petrizi V, Ravelli E, Gentile M, Urbano MA, Franceschetti S, Ghione P, Orsucci L, Frustaci AM, Gaidano G, Vitolo U, Morra E. *Leuk Lymphoma*. 2015;14:1-6

62. *Immunoglobulin heavy variable (IGHV) genes and alleles: new entities, new names and implications for research and prognostication in chronic lymphocytic leukaemia.* Xochelli A, Agathangelidis A, Kavakiotis I, Minga E, Sutton LA, Baliakas P, Chouvarda I, Giudicelli V, Vlahavas I, Maglaveras N, Bonello L, Trentin L, **Tedeschi A**, Panagiotidis P, Geisler C, Langerak AW, Pospisilova S, Jelinek DF, Oscier D, Chiorazzi N, Darzentas N, Davi F, Ghia P, Rosenquist R, Hadzidimitriou A, Belessi C, Lefranc MP, Stamatopoulos K. *Immunogenetics*. 2015;67(1):61-6.
61. *Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients* Montillo M, **Tedeschi A**, Gaidano G, Coscia M, Petrizzi VB, Orlandi E, Cascavilla N, Ghia P, Motta M, Gallamini A, Frustaci AM, Rossi D, De Paoli L, Nichelatti M, Morra E, Massaia M. *Haematologica*. 2014;99(9):e159-61.
60. *Associated cancers in Waldenström macroglobulinemia: clues for common genetic predisposition.* Morra E, Varettoni M, **Tedeschi A**, Arcaini L, Ricci F, Pascutto C, Rattotti S, Vismara E, Paris L, Cazzola M. *Clin Lymphoma Myeloma Leuk*. 2013;13(6):700-3
59. *Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).* Dimopoulos MA, García-Sanz R, Gavriatopoulou M, Morel P, Kyrtsolis MC, Michalis E, Kartasis Z, Leleu X, Palladini G, **Tedeschi A**, Gika D, Merlini G, Kastritis E, Sonneveld P. *Blood*. 2013;122(19):3276-82.
58. *Use it again!': retherapy with bendamustine in indolent B-cell lymphoproliferative disorders.* Montillo M, **Tedeschi A**. *Expert Rev Hematol*. 2013 Jun;6(3):247-50
57. *Should a positive direct antiglobulin test be considered a prognostic predictor in chronic lymphocytic leukemia?* Ricci F, **Tedeschi A**, Vismara E, Colombo C, Veronese S, Nichelatti M, Cairoli R, Morra E, Montillo M. *Clin Lymphoma Myeloma Leuk*. 2013;13(4):441-6
56. *Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts.* Chiaretti S, Vitale A, Cazzaniga G, Orlando SM, Silvestri D, Fazi P, Valsecchi MG, Elia L, Testi AM, Mancini F, Conter V, te Kronnie G, Ferrara F, Di Raimondo F, **Tedeschi A**, Fioritoni G, Fabbiano F, Meloni G, Specchia G, Pizzolo G, Mandelli F, Guarini A, Basso G, Biondi A, Foà R. *Haematologica*. 2013;98(11):1702-10
55. *Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemia.* Tedeschi A, Ricci F, Goldaniga MC, Benevolo G, Varettoni M, Motta M, Pioltelli P, Gini G, Barate' C, Luraschi A, Vismara E, Frustaci AM, Nichelatti M, Vitolo U, Baldini L, Morra E. *Clin Lymphoma Myeloma Leuk*. 2013;13(2):231-4
54. *Microarray demonstrates different gene expression profiling signatures between Waldenström macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.* Trojani A, Greco A, Tedeschi A, Lodola M, Di Camillo B, Ricci F, Turrini M, Varettoni M, Rattotti S, Morra E. *Clin Lymphoma Myeloma Leuk*. 2013;13(2):208-10.
53. *Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.* Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G, Garcia-Sanz R, Ocio EM, Morra E, Morel P, Anderson KC, Patterson CJ, Munshi NC, **Tedeschi A**, Joshua DE, Kastritis E, Terpos E, Ghobrial IM, Leleu X, Gertz MA, Ansell SM, Morice WG, Kimby E, Treon SP; VIth International Workshop on Waldenström macroglobulinaemia. *Br J Haematol*. 2013;160(2):171-6.
52. *Impact of B-cell count and imaging screening in cMBL: any need to revise the current guidelines?* Scarfò L, Zibellini S, **Tedeschi A**, Maura F, Neri A, Bertazzoni P, Sarina B, Nalli G, Motta M, Rossini F, Cortelezzi A, Montillo M, Orlandi E, Ghia P. *Leukemia*. 2012;26(7):1703-7
51. *Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation.* Ferrario A, Pulsoni A, Olivero B, Rossi G, Vitolo U, **Tedeschi A**, Merli F, Rigacci L, Stelitano C, Goldaniga M, Mannina D, Musto P, Rossi F, Gamba E, Baldini L. *Cancer*. 2012;118(16):3954-61
50. *The coexistence of chronic lymphocytic leukemia and myeloproliferative neoplasms: a retrospective multicentric GIMEMA experience.* Laurenti L, Tarnani M, Nichele I, Ciolli S, Cortelezzi A, Forconi F, Rossi D, Mauro FR, D'Arena G, Del Poeta G, Montanaro M, Morabito F, Musolino C, Callea V, Falchi L, **Tedeschi A**, Ambrosetti A, Gaidano G, Leone G, Foà R. *Am J Hematol*. 2011;86(12):1007-12.

49. *Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom's Macroglobulinemia.* Ricci F, **Tedeschi A**, Montillo M, Morra E. *Mediterr J Hematol Infect Dis.* 2011;3(1)
48. *An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia.* Montillo M, **Tedeschi A**, Petrizzi VB, Ricci F, Crugnola M, Spriano M, Spedini P, Ilariucci F, Uziel L, Attolico I, Vismara E, De Blasio A, Zaccaria A, Morra E. *Blood.* 2011;118(15):4079-85
47. *Three copies of isochromosome 8q in Ph+ B-cell acute lymphoblastic leukemia.* Soriani S, Fedeli F, Molteni A, Grillo G, **Tedeschi A**, Scarpati B, Campidelli C, Leszl A, Farioli R, De Canal G, Mura MA, Cesana C. *Leuk Res.* 2011;35(11):e217-9
46. *Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease.* **Tedeschi A**, Benevolo G, Varettoni M, Battista ML, Zinzani PL, Visco C, Meneghini V, Pioltelli P, Sacchi S, Ricci F, Nichelatti M, Zaja F, Lazzarino M, Vitolo U, Morra E. *Cancer.* 2012; 118(2):434-43
45. *Risk of second cancers in Waldenström macroglobulinemia.* Varettoni M, **Tedeschi A**, Arcaini L, Pascutto C, Vismara E, Orlandi E, Ricci F, Corso A, Greco A, Mangiacavalli S, Lazzarino M, Morra E. *Ann Oncol.* 2012;23(2):411-5
44. *The impact of advanced age according to IPSSWM cut-off on the outcome of symptomatic and asymptomatic Waldenström's macroglobulinemia at diagnosis.* Ricci F, **Tedeschi A**, Vismara E, Greco A, Montillo M, Nichelatti M, Varettoni M, Lazzarino M, Morra E. *Clin Lymphoma Myeloma Leuk.* 2011;11(1):124-6
43. *Factors predicting transformation of asymptomatic IgM monoclonal gammopathy.* Greco A, **Tedeschi A**, Varettoni M, Nichelatti M, Paris L, Ricci F, Vismara E, Morra E. *Clin Lymphoma Myeloma Leuk.* 2011;11(1):77-9
42. *Relationship between pharmacokinetic profile of subcutaneously administered alemtuzumab and clinical response in patients with chronic lymphocytic leukemia.* Montagna M, Montillo M, Avanzini MA, Tinelli C, **Tedeschi A**, Visai L, Ricci F, Vismara E, Morra E, Regazzi M. *Haematologica.* 2011;96(6):932-6
41. *The spectrum of use of rituximab in chronic lymphocytic leukemia.* **Tedeschi A**, Vismara E, Ricci F, Morra E, Montillo M. *Onco Targets Ther.* 2010;3:227-46
40. *Gene expression profiling identifies ARSD as a new marker of disease progression and the sphingolipid metabolism as a potential novel metabolism in chronic lymphocytic leukemia.* Trojani A, Di Camillo B, **Tedeschi A**, Lodola M, Montesano S, Ricci F, Vismara E, Greco A, Veronese S, Orlacchio A, Martino S, Colombo C, Mura M, Nichelatti M, Colosimo A, Scarpati B, Montillo M, Morra E. *Cancer Biomark.* 2011-2012;11(1):15-28
39. *Bendamustine: new perspective for an old drug in lymphoproliferative disorders.* Montillo M, Ricci F, **Tedeschi A**, Vismara E, Morra E. *Expert Rev Hematol.* 2010 Apr;3(2):131-48
38. *ZAP-70, IgVh, and cytogenetics for assessing prognosis in chronic lymphocytic leukemia.* Trojani A, Montillo M, Nichelatti M, **Tedeschi A**, Colombo C, Veronese S, Mura MA, Ricci F, Scarpati B, Colosimo A, Lodola M, Morra E. *Cancer Biomark.* 2010;6(1):1-9
37. *Fludarabine in the treatment of chronic lymphocytic leukemia: a review.* Ricci F, **Tedeschi A**, Morra E, Montillo M. *Ther Clin Risk Manag.* 2009;5(1):187-207
36. *Fludarabine-based combination therapies for Waldenström's macroglobulinemia.* **Tedeschi A**, Alamos SM, Ricci F, Greco A, Morra E. *Clin Lymphoma Myeloma.* 2009;9(1):67-70
35. *Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia.* Montillo M, Ricci F, **Tedeschi A**, Cafro AM, Nosari AM, Nichelatti M, Marbello L, Morra E. *Leuk Res.* 2009;33(8):1072-8
34. *Outcome of hyperleukocytic adult acute myeloid leukaemia: a single-center retrospective study and review of literature.* Marbello L, Ricci F, Nosari AM, Turrini M, Nador G, Nichelatti M, **Tedeschi A**, Vismara E, Morra E. *Leuk Res.* 2008;32(8):1221-7.
33. *Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL).* Montillo M, Ricci F, Miqueleiz S, **Tedeschi A**, Morra E. *Biologics.* 2008;2(1):41-52

32. *Characteristics and stage of the underlying diseases could determine the risk of opportunistic infections in patients receiving alemtuzumab.* Nosari A, **Tedeschi A**, Ricci F, Montillo M. *Haematologica*. 2008;93(2):e30-1
31. *Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.* Molica S, Montillo M, Ribatti D, Mirabelli R, **Tedeschi A**, Ricci F, Veronese S, Vacca A, Morra E. *Haematologica*. 2007;92(10):1367-74
30. *Cryoglobulinemia.* **Tedeschi A**, Baratè C, Minola E, Morra E. *Blood Rev*. 2007;21(4):183-200.
29. *High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.* Tedeschi A, Montillo M, Strocchi E, Cafro AM, Tresoldi E, Intropido L, Nichelatti M, Marbello L, Baratè C, Camaggi CM, Morra E. *Cancer Chemother Pharmacol*. 2007;59(6):771-9
28. *Role of fludarabine in hematological malignancies.* Montillo M, Ricci F, Tedeschi A. *Expert Rev Anticancer Ther*. 2006;6(9):1141-61
27. *Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.* Montillo M, Tedeschi A, Miqueleiz S, Veronese S, Cairoli R, Intropido L, Ricci F, Colosimo A, Scarpati B, Montagna M, Nichelatti M, Regazzi M, Morra E. *J Clin Oncol*. 2006;24(15):2337-42.
26. *The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trial.* Cimino G, Pane F, Elia L, Finolezzi E, Fazi P, Annino L, Meloni G, Mancini M, **Tedeschi A**, Di Raimondo F, Specchia G, Fioritoni G, Leoni P, Cuneo A, Mecucci C, Saglio G, Mandelli F, Foà R; GIMEMA Leukemia Working Party. *Haematologica*. 2006;91(3):377-80
25. *A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol.* Mancini M, Scappaticci D, Cimino G, Nanni M, Derme V, Elia L, Tafuri A, Vignetti M, Vitale A, Cuneo A, Castoldi G, Saglio G, Pane F, Mecucci C, Camera A, Specchia G, **Tedeschi A**, Di Raimondo F, Fioritoni G, Fabbiano F, Marmont F, Ferrara F, Cascavilla N, Todeschini G, Nobile F, Kropp MG, Leoni P, Tabilio A, Luppi M, Annino L, Mandelli F, Foà R. *Blood*. 2005;105(9):3434-41
24. *High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation.* Cairoli R, Grillo G, **Tedeschi A**, D'Avanzo G, Marengo P, Morra E. *Haematologica*. 2004;89(3):361-3
23. *Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H.* Montillo M, **Tedeschi A**, Rossi V, Cairoli R, Pungolino E, Intropido L, Cafro AM, D'Avanzo G, Farioli R, Brando B, Scarpati B, Veronese S, Morra E. *Leukemia*. 2004;18(1):57-62
22. *C-Kit point mutations in core binding factor leukemias: correlation with white blood cell count and the white blood cell index.* Cairoli R, Grillo G, Beghini A, **Tedeschi A**, Ripamonti CB, Larizza L, Morra E. *Leukemia*. 2003;17(2):471-2. No abstract available.
21. *Interphase fluorescence in situ hybridization analysis of del(11)(q23) and del(17)(p13) in chronic lymphocytic leukemia. a study of 40 early-onset patients.* Doneda L, Montillo M, Intropido L, **Tedeschi A**, Morra E, Larizza L. *Cancer Genet Cytogenet*. 2003;140(1):31-6
20. *Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia.* Montillo M, **Tedeschi A**, O'Brien S, Di Raimondo F, Lerner S, Ferrajoli A, Morra E, Keating MJ. *Cancer*. 2003;97(1):114-20
19. *Molecular remission and reconstitution of a full chimera with arsenic trioxide in a patient with acute promyelocytic leukemia relapsed after allogeneic bone marrow transplantation.* **Tedeschi A**, Cairoli R, Marengo P, Nosari A, Tresoldi E, Di Bona E, Montillo M, Morra E. *Leukemia*. 2002;16(12):2455-6
18. *Partial deletions of long arm of chromosome 6: biologic and clinical implications in adult acute lymphoblastic leukemia.* Mancini M, Vegna ML, Castoldi GL, Mecucci C, Spirito F, Elia L, Tafuri A, Annino L, Pane F, Rege-Cambrin G, Gottardi M, Leoni P, Gallo E, Camera A, Luciano L, Specchia G, Torelli G, Sborgia M, Gabbas A, **Tedeschi A**, Della Starza I, Cascavilla N, Di Raimondo F, Mandelli F, Foà R. *nLeukemia*. 2002;16(10):2055-61.
17. *MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia.* Tafuri A, Gregorj C, Petrucci MT, Ricciardi MR, Mancini M, Cimino G, Mecucci C, **Tedeschi A**,

Fioritoni G, Ferrara F, Di Raimondo F, Gallo E, Liso V, Fabbiano F, Cascavilla N, Pizzolo G, Camera A, Pane F, Lanza F, Cilloni D, Annino L, Vitale A, Vegna ML, Vignetti M, Foà R, Mandelli F; GIMEMA Group. *Blood*. 2002;100(3):974-81.

16. *Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine*. Montillo M, Cafo AM, **Tedeschi A**, Brando B, Oreste P, Veronese S, Rossi V, Cairoli R, Pungolino E, Morra E. *Haematologica*. 2002;87(7):695-700

15. *Prior invasive pulmonary and cerebellar mucormycosis is not a primary contraindication to perform an autologous stem cell transplantation in leukemia*. **Tedeschi A**, Montillo M, Cairoli R, Marengo P, Cafo A, Oreste P, Nosari A, Morra E. *Leuk Lymphoma*. 2002;43(3):657-9.

14. *Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis*. Cairoli R, Grillo G, **Tedeschi A**, Gargantini L, Marengo P, Tresoldi E, Barbarano L, Nosari AM, Morra E. *Bone Marrow Transplant*. 2002;29(6):473-7

13. *The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease*. DiRaimondo F, Albitar M, Huh Y, O'Brien S, Montillo M, **Tedeschi A**, Kantarjian H, Lerner S, Giustolisi R, Keating M. *Cancer*. 2002;94(6):1721-30.

12. *Detection of BCR/ABL rearrangements in adult acute lymphoblastic leukemia using a highly sensitive interphase fluorescence in situ hybridization method (D-FISH)*. Mancini M, Nanni M, Sirleto P, De Cuia MR, Castoldi GL, Cilloni D, Cimino G, Mecucci C, Pane F, Annino L, Di Raimondo F, Santoro A, Specchia G, **Tedeschi A**, Todeschini G, Foà R; GIMEMA study group. *Hematol J*. 2001;2(1):54-60

11. *Invasive aspergillosis in haematological malignancies: clinical findings and management for intensive chemotherapy completion*. Nosari A, Oreste P, Cairoli R, Montillo M, Carrafiello G, Astolfi A, Muti G, Marbello L, **Tedeschi A**, Magliano E, Morra E. *Am J Hematol*. 2001;68(4):231-6

10. *Multicolor FISH in chronic lymphocytic leukemia. An interphase study of patients with early-onset disease*. Doneda L, Castorina P, **Tedeschi A**, Intropido L, Morra E, Montillo M, Larizza L. *Cancer Genet Cytogenet*. 2001;125(1):63-9

9. *Feasibility of peripheral blood stem cell rescue as intensification in elderly patients with acute myelocytic leukaemia: a pilot study from the Gimema Group. Gruppo Italiano Malattie Ematologiche Maligne Dell'Adulto*. Montillo M, **Tedeschi A**, Pagano L, Venditti A, Ferrara F, Fabris P, Martino B, Musso M, De Rosa G, Specchia G, Monaco M, Sparaventi G, Spadea A, Palmas A, Deplano W, Manna A, Melillo L, Miraglia E, Mirto S, Mandelli F. *Br J Haematol*. 2000;111(1):334-7

8. *Treatment of chronic myeloid leukemia in the blastic phase with fludarabine, cytosine arabinoside and G-CSF (FLAG)*. **Tedeschi A**, Montillo M, Ferrara F, Nosari A, Mele G, Copia C, Leoni P, Morra E. *Eur J Haematol*. 2000;64(3):182-7

7. *Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma*. Lazzarino M, Orlandi E, Montillo M, **Tedeschi A**, Pagnucco G, Astori C, Corso A, Brusamolino E, Simoncini L, Morra E, Bernasconi C. *Ann Oncol*. 1999;10(1):59-64

6. *Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia*. Montillo M, Mirto S, Petti MC, Latagliata R, Magrin S, Pinto A, Zagonel V, Mele G, **Tedeschi A**, Ferrara F. *Am J Hematol*. 1998;58(2):105-9

5. *Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony-stimulating factor (FLAG-GCSF)*. Montillo M, **Tedeschi A**, Centurioni R, Leoni P. *Leuk Lymphoma*. 1997;25(5-6):579-83

4. *Effectiveness of fludarabine in advanced B-cell chronic lymphocytic leukemia*. Montillo M, **Tedeschi A**, Delfini C, Olivieri A, D'Adamo F, Leoni P. *Tumori*. 1995;81(6):419-23

3. *Acute renal failure as a consequence of urine stop flow in a patient with chronic lymphocytic leukemia after treatment with fludarabine*. Montillo M, **Tedeschi A**, Leoni P. *Am J Hematol*. 1995;50(1):73-4.

2. *Recurrence of autoimmune thrombocytopenia after treatment with fludarabine in a patient with chronic lymphocytic leukemia*. Montillo M, **Tedeschi A**, Leoni P. *Leuk Lymphoma*. 1994;15(1-2):187-8

1. *PBSC collection after high dose chemotherapy followed by G-CSF in patients with malignancies: analysis of results regarding factors affecting the yield of hemopoietic progenitors.* Olivieri A, Offidani M, Ciniero L, Poloni A, **Tedeschi A**, Refe MC, Strusi AS, Leoni P. *Int J Artif Organs.* 1993 ;16 Suppl 5:57-63